Physician profile
Zhen Lu
NPI 1528424090
$972.88
in general payments reported to CMS, 2019-2025
18 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $68.42 · 2021: $231 · 2023: $161 · 2024: $281 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $177.73 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $124.91 | 2023 | Breztri |
| Glaxosmithkline, LLC. | $120.96 | 2025 | Shingrix |
| Gilead Sciences, INC. | $97.33 | 2024-2025 | |
| Ethicon US, LLC | $68.42 | 2020 | |
| Janssen Pharmaceuticals, INC | $63.00 | 2024 | Spravato |
| Integra Lifesciences Corporation | $53.15 | 2021 | |
| Axsome Therapeutics, INC. | $53.09 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.58 | 2023-2024 | Xifaxan |
| Novo Nordisk INC | $31.21 | 2024 | Ozempic, Rybelsus, Wegovy |
| Biogen, INC. | $19.98 | 2025 | Skyclarys |
| Abbvie INC. | $19.31 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.65 | 2024 | Entyvio |
| Bayer Healthcare Pharmaceuticals INC. | $17.15 | 2025 | |
| Collegium Pharmaceutical, INC. | $16.41 | 2025 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.08 | 2025 | |
| Esperion Therapeutics, INC. | $15.37 | 2025 | Nexletol |
| Merck Sharp & Dohme LLC | $14.55 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhen Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.